Premorbid use of statins is associated with higher recanalization rates in patients with acute ischemic stroke undergoing endovascular treatment

Journal of Neuroimaging

Volumn 19, Issue 1, 2009, Pages 19-22

  Georgiadis, Alexandros L ^a   Hussein, Haitham M ^a   Vazquez, Gabriela ^a   Shah, Qaisar ^a   Suri, M Fareed K ^a   Ezzeddine, Mustapha A ^a   Qureshi, Adnan I ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

Author keywords

Endovascular treatment; Intra arterial thrombolysis; Ischemic stroke; Recanalization; Statins

Indexed keywords

ALTEPLASE; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICARDIPINE; RETEPLASE;

ADULT; AGED; ANGIOPLASTY; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; DRUG USE; ENDOVASCULAR SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; QURESHI SCALE; RATING SCALE; RECANALIZATION; RETROSPECTIVE STUDY; STENT;

AGED; BRAIN ISCHEMIA; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 58149333679     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2008.00319.x     Document Type: Article

References (12)

1. Williams LS, Yilmaz EY, Lopez-Yunez AM. Retrospective assessment of initial stroke severity with the NIH stroke scale. Stroke 2000;31:858-862.
2. Qureshi AI. New grading system for angiographic evaluation of arterial occlusions and recanalization response to intra-arterial thrombolysis in acute ischemic stroke. Neurosurgery 2002;50(6):1405-1414.
3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333(20):1301-1307..
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001-1009.
5. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 2001;285(13):1711-1718.
6. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000;355(9222):2218-2219.
7. Sparks DL, Sabbagh M, Connor D, et al. Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:78-86.
8. Palinski W, Napoli C. Unraveling pleiotropic effects of statins on plaque rupture. Arterioscler Thromb Vasc Biol 2002;22:1745-1750.
9. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118.
10. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 1998;18(11):1163-1172.
11. Amarenco P, Bogousslavsky J, Callahan A III, et al. Stroke prevention by aggressive reduction in cholesterol levels (SPARCL) Investigators. N Engl J Med 2006;355(6):613-615.
12. Collins R, Armitage J, Parish S, et al. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363(9411):757-767.